Gelesis100

DEVICE4 trials

Sponsors

Gelesis, Inc., Purdue University

Conditions

Appetitive BehaviorHealthy Overweight ObeseObesityOverweight

Unknown Phase

Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes

CompletedNCT02307279

Gelesis, Inc.Obesity, Overweight

Start: 2014-11-30End: 2017-06-30Updated: 2022-08-30

A Scintigraphic Study to Investigate the Effect of Gelesis100 on Gastric Emptying in Overweight and Obese Subjects

CompletedNCT02487602

Gelesis, Inc.Obesity, Overweight

Start: 2015-09-30End: 2016-07-31Updated: 2016-08-23

The Effect of Gelesis100 on the Pharmacokinetics of Metformin

CompletedNCT02524821

Gelesis, Inc.Healthy Overweight Obese

Start: 2015-09-30End: 2015-12-31Updated: 2018-06-26

SATISFY (geleSis100 Effects on AppeTIte Sensations, Feeding Behavior and Dietary energY)

CompletedNCT04257123

Purdue UniversityAppetitive Behavior

Start: 2020-01-07End: 2021-12-31Updated: 2022-04-19

Related Papers

1234-P: Impact of Treatment Adherence to Observed Weight Loss in the GLOW Study

Diabetes2021-06-01

SAT-LB023 Elevated Fasting Plasma Glucose Predicts Higher Odds For Becoming A Super-responder With Gelesis100 In The GLOW Pivotal Weight-loss Study

Journal of the Endocrine Society2019-04-01

MON-112 Gelesis100 Reduces Insulin Resistance in Patients Who Are Overweight or Have Obesity with High Insulin Resistance: Results of the GLOW Study

Journal of the Endocrine Society2019-04-01